Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment his Department has made of recently published research from Breast Cancer Now on the availability of bisphosphonates.

The Independent Cancer Taskforce report included a specific recommendation on the use of adjuvant bisphosphonates for treating people with breast cancer. We understand that NHS England is working to realise the ambitions set out in the report and will publish an update on progress made soon.

National prescribing arrangements already allow for bisphosphonates to be prescribed for the prevention of secondary breast cancer.

Updated guidance from the National Institute for Health and Care Excellence on the use of adjuvant bisphosphonates for the management of breast cancer treatment-induced bone loss, taking into account the latest available evidence, is expected in July 2018.